Selectquote, Inc (SLQT) 2026 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Welcome to SelectQuote's second quarter earnings conference call. (Operator Instructions) It is now my pleasure to introduce Matt Gunter, Select Investor Relations. Mr. Gunter, you may begin the conference.

    歡迎參加 SelectQuote 第二季財報電話會議。(接線員指示) 現在我很榮幸介紹 Select 投資人關係部的 Matt Gunter。Gunter 先生,您可以開始會議。

  • Matthew Gunter - Chief Experience Officer

    Matthew Gunter - Chief Experience Officer

  • Thank you and good morning everyone. Welcome to Select Quotes fiscal second quarter earnings call. Before we begin our call, I would like to mention that on our website, we have provided a slide presentation to help guide our discussion. After today's call, a replay will also be available on our website. Joining me from the company, I have our Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement. Following Tim and Ryan's comments today, we will also have a question-and-answer session.

    謝謝,各位早安。歡迎參加 SelectQuote 會計年度第二季財報電話會議。在開始之前,我想提到我們已在官網提供簡報投影片,以協助引導今天的討論。今天會議結束後,官網也將提供重播。與我一同出席的公司代表包括執行長 Tim Danker 與財務長 Ryan Clement。在 Tim 與 Ryan 今天的發言之後,我們也將進行問答環節。

  • As referenced on [slide 2] during this call, we will be discussing some non-GAAP financial measures. The most directly comparable GAAP financial measures and a reconciliation of the differences between the GAAP and non-GAAP financial measures are available in our earnings release and investor presentation on our website.

    如本次電話會議中[投影片 2]所述,我們將討論部分非 GAAP 財務衡量指標。與之最直接可比的 GAAP 財務衡量指標,以及 GAAP 與非 GAAP 財務衡量指標差異的調節表,已載於我們官網的財報新聞稿與投資人簡報中。

  • And finally, a reminder that certain statements made today may be forward-looking statements. These statements are made based upon management's current expectations and beliefs concerning future events impacting the company and therefore involve a number of uncertainties and risks, including but not limited to those described in our earnings release.

    最後提醒,今天所作的某些陳述可能屬於前瞻性陳述。這些陳述係基於管理層目前對影響公司之未來事件的預期與信念,因此涉及多項不確定性與風險,包括但不限於我們財報新聞稿中所述者。

  • Annual report on Form 10-K for the period ended June 30, 2025, and subsequent filings with the SEC. Therefore, the actual results of operations or financial condition of the company could differ materially from those expressed or implied in our forward-looking statements.

    截至 2025 年 6 月 30 日止期間之 Form 10-K 年度報告,以及其後向 SEC 提交的文件。因此,公司實際營運結果或財務狀況可能與我們前瞻性陳述中明示或暗示者存在重大差異。

  • And with that, I'd like to turn the call over to our Chief Executive Officer, Tim Danker. Tim.

    接下來,我想把電話會議交給我們的執行長 Tim Danker。Tim。

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • Thanks, Matt. Good morning and thank you for joining us. It was a strong quarter for SelectQuote in a number of ways, which I'll summarize on [slide 3]. As you saw from our press release, our team's execution this Medicare Advantage season drove a successful AEP. Despite another shifting backdrop for policy features, SelectQuote continues to prove its value to customers as a leading choice marketplace.

    謝謝,Matt。各位早安,感謝各位加入我們。對 SelectQuote 而言,本季在多個方面表現強勁,我將在[投影片 3]上做摘要。如各位從我們的新聞稿所見,我們團隊在本次 Medicare Advantage 季節的執行帶動了成功的 AEP。儘管保單特色的外部環境再度變動,SelectQuote 仍持續證明其價值,作為領先的選擇型市集,成為客戶的重要選擇。

  • As always, seniors receive bespoke information and assistance from live agents to select the policy that best fits their needs. Better yet, our commitment to technology continues to arm our agents with an efficient and powerful service platform which drove another strong quarter for agent productivity, aiding volume production and profitability.

    一如既往,銀髮族可透過真人專員獲得量身打造的資訊與協助,以選擇最符合其需求的保單。更重要的是,我們對科技的投入持續為專員提供高效率且強大的服務平台,帶動專員生產力再創強勁一季,進而提升承保量與獲利能力。

  • Strong operational execution and marketing efficiency drove near record senior EBITDA margins of 39% on modest growth year over year. Congrats to the team for yet again driving an AP quarter with strong operating leverage and another dynamic market backdrop.

    強勁的營運執行與行銷效率,帶動銀髮族業務 EBITDA 利潤率接近歷史高點,達 39%,在年對年溫和成長下仍表現亮眼。恭喜團隊再次在具備強勁營運槓桿、且市場環境多變的背景下,交出一個表現出色的 AP 季度。

  • Beyond senior, our healthcare services segment continues to grow rapidly, increasing revenue 26% year over year. Most importantly, [SelectRx] continues to make a significant impact on the health and quality of life for America's growing senior population. The impact is real and is being increasingly noticed. This is great validation of the clinical value SelectRx provides beyond simple drug delivery.

    除銀髮族業務外,我們的醫療保健服務事業部持續快速成長,營收年增 26%。最重要的是,[SelectRx] 持續對美國日益成長的銀髮族人口之健康與生活品質帶來顯著影響。這項影響是真實存在的,且正受到越來越多的關注。這也充分驗證 SelectRx 所提供的臨床價值,不僅僅是單純的藥品配送。

  • I'll speak more to that topic in a moment. Additionally, over the past month, we made two announcements which benefit our SelectRx business and capital flexibility. First, for SelectRx, we entered a multi-year agreement with one of our most important pharmacy benefit managers, our PBM partners. With this agreement, Select's visibility into drug reimbursement pricing is significantly improved, which is critically beneficial to our strategic priority to expand profitability.

    我稍後會再就此主題多談一些。此外,在過去一個月,我們發布了兩項公告,將有利於我們的 SelectRx 業務與資本彈性。首先,就 SelectRx 而言,我們與最重要的藥局福利管理機構之一(PBM 合作夥伴)簽訂了一項多年期協議。透過此協議,Select 對藥品給付/報銷定價的可視性大幅提升,這對我們擴大利潤的策略優先事項至關重要。

  • Second, our new $415 million credit facility announced in mid-January greatly improves the company's capital flexibility, which is an important milestone in our ability to drive consistent profitable growth. Overall, we are very pleased with our results to date and have greater conviction in our ability to compound profitability and cash flow given this past month's announcement.

    第二,我們於 1 月中旬宣布的新 4.15 億美元信貸融資,大幅提升公司的資本彈性,這是我們推動穩定獲利成長能力上的重要里程碑。整體而言,我們對目前為止的成果非常滿意,且鑑於過去一個月的公告,我們對於持續累積獲利能力與現金流的能力更具信心。

  • Lastly, despite another strong quarter, a recent action by a national carrier partner requires that we lower our fiscal '26 guidance. Specifically, this carrier significantly cut their strategic marketing budget across all distribution channel partners, including Select.

    最後,儘管本季表現依然強勁,但一位全國性保險公司合作夥伴近期的行動,要求我們下調 2026 會計年度的財測指引。具體而言,該保險公司在所有分銷通路合作夥伴(包括 Select)大幅削減其策略性行銷預算。

  • As we've discussed, insurance companies continue to optimize profitability for Medicare Advantage. In conversations with the carrier, the decision was designed to slow growth following above trend growth on MA.

    如我們先前所討論,保險公司持續就 Medicare Advantage 的獲利能力進行最佳化。在與該保險公司的對話中,這項決策旨在於 MA 出現高於趨勢的成長之後,放緩成長速度。

  • In total, we expect the fiscal '26 impact from this carrier action to be around $20 million. Combined with the PDM reimbursement impact we discussed last quarter, which we know now will also create an impact of around $20 million. We need to reduce our guidance ranges for both consolidated revenue and adjusted EBITDA to reflect the $40 million aggregate impact.

    整體而言,我們預期該保險公司此項行動對 2026 會計年度的影響約為 2,000 萬美元。再加上我們上季討論的 PDM 報銷影響,我們現在也確認其影響約為 2,000 萬美元。因此,我們需要下調合併營收與調整後 EBITDA 的指引區間,以反映合計 4,000 萬美元的總影響。

  • While frustrating, it's important to note that the change by this one carrier does not impact our long-term outlook about the growth, profitability, and cash flow potential for our business. We stand by our previously announced fiscal '26 targets of 20% plus EBITDA margins for our senior division and an annualized adjusted EBITDA exit rate of $40 million to $50 million for our healthcare services division.

    雖然令人沮喪,但需要強調的是,這一家保險公司的變動並不影響我們對業務長期成長、獲利能力與現金流潛力的展望。我們仍維持先前公布的 2026 會計年度目標:銀髮族事業部 EBITDA 利潤率達 20% 以上,以及醫療保健服務事業部年化調整後 EBITDA 期末退出率達 4,000 萬至 5,000 萬美元。

  • Additionally, we think it's important to note the substantial improvements Slow has made on cash flow generation despite the PBM and the action of this one carrier. We expect fiscal '26 to produce operating cash flow of $25million to $35 million, which is up more than $40 million at the midpoint compared to last year. The improvement has been driven by increased cash flow from our healthcare services business and continued progress to optimize our capital structure.

    此外,我們也認為有必要指出,儘管受到 PBM 與該保險公司行動的影響,Select 在現金流創造方面仍取得顯著改善。我們預期 2026 會計年度的營運現金流將達 2,500 萬至 3,500 萬美元,以中位數計較去年增加超過 4,000 萬美元。此改善主要來自醫療保健服務業務帶來的現金流增加,以及我們持續推進資本結構最佳化。

  • Overall, while the noise in our EBITDA driven by partner actions was not anticipated, we're very pleased with the execution and trajectory of our profitability and cash flow. Put another way, [lewood] is delivering on the goals of our strategy, and we're confident in our ability to drive value for shareholders. With that, let's move this slide forward to review our performance in AEP.

    整體而言,雖然合作夥伴行動所造成的 EBITDA 雜音並非事前所預期,但我們對獲利能力與現金流的執行與走勢仍感到非常滿意。換句話說,[lewood] 正在實現我們策略目標,我們也有信心為股東創造價值。接下來,讓我們翻到下一張投影片,回顧我們在 AEP 的表現。

  • Similar to the past Medicare Advantage season, we prepared early for a season of disruption given shifting policy and volume strategies across the industry. As we noted last quarter, our strategy entering AEP was to focus on tenured agent retention and proactive connection with our policyholders on their needs relative to changes in the overall policy landscape.

    與過去的 Medicare Advantage 季節類似,鑑於全產業在保單與量能策略上的變動,我們提早為一個充滿干擾的季節做好準備。如我們上季所提到,我們在進入 AEP 時的策略,是聚焦於資深專員留任,並主動與保戶連結,了解其需求相對於整體保單環境變化的影響。

  • This focus resulted in another successful season. Policy volume growth was 4%, modestly ahead of our expectations. Agents and technology perform well again, measured by productivity and profitability. Senior grew EBITDA by 2% and drove near record margins of 39%, which marks the fourth consecutive AEP season of senior EBITDA margins above 30% despite highly varied years for Medicare Advantage policy features.

    這項聚焦帶來了另一個成功的季度。保單量成長4%,略高於我們的預期。以生產力與獲利能力衡量,代理人與科技再次表現出色。Senior 的 EBITDA 成長2%,並推動接近歷史新高的39%利潤率;這也標誌著在 Medicare Advantage 保單特色高度多變的年份中,Senior 已連續第四個 AEP 季度的 EBITDA 利潤率高於30%。

  • We're proud of the track record and believe the strategy to prioritize profitable growth in cash flow has been more than battle tested at this point. Our team delivered strong agent productivity and highly efficient marketing cost per policy once again.

    我們為這項成績紀錄感到自豪,並相信以現金流為核心、優先追求具獲利性的成長之策略,至今已充分經過市場考驗。我們的團隊再次交出強勁的代理人生產力,以及高度效率的每張保單行銷成本。

  • First, our agent population was comprised of a slightly lower, albeit still strong mix of tenured agents than the previous year. Our agent retention remained steady at north of 90%, but our tenured agent mix was lower due to additional agent hiring this past summer. Even with this higher mix of new agents, our productivity per agent remained 12% higher than two years ago, which is a testament to the effectiveness of our information and technology investments. Which have always been a pillar of our model.

    首先,我們的代理人組成相較前一年,資深代理人的占比略低,但整體仍維持強勁。我們的代理人留任率仍穩定維持在90%以上,但由於去年夏天額外招募代理人,資深代理人占比有所下降。即便新進代理人占比較高,我們每位代理人的生產力仍較兩年前高出12%,這證明我們在資訊與科技投資上的成效。而這些投資一直是我們商業模式的支柱。

  • In regards to marketing, you'll recall last season's marketing spend per approved policy was highly efficient. We've continued to refine our customer targeting and have placed intentional focus on owned and operated marketing channels which provide a strong mix of attractive prospects, specifically our marketing cost per approved policy, and this AEP was [$326] which is in line with last year and 20% lower than [Q2] fiscal '24.

    在行銷方面,您會記得上一季每張核准保單的行銷支出非常有效率。我們持續精進客戶鎖定,並刻意聚焦於自有與自營的行銷通路,以提供具吸引力的潛在客群組合;具體而言,本次 AEP 每張核准保單的行銷成本為[$326],與去年相當,且較[Q2] 2024 會計年度低20%。

  • To summarize, the unique strengths of our model drove significant value to our policyholders and carrier partners and another dynamic environment for Medicare Advantage. This resulted in impressive profitability and cash flow for our senior segment.

    總結而言,我們模式的獨特優勢為保戶與保險公司合作夥伴創造了顯著價值,也因應了 Medicare Advantage 的另一個充滿變動的環境。這使我們的 senior 事業部門展現亮眼的獲利能力與現金流。

  • On slide 5, I'd like to provide additional real-world color on how SEO helps America's seniors when the market is dynamic and disruptive. At the highest level, select quotes optimized technology and data empowers our live agents to deliver excellent service to our customers.

    在第5頁投影片,我想補充一些實務面的說明,談談當市場充滿變動與干擾時,SEO 如何協助美國的長者。從最高層次來看,Select Quotes 最佳化的科技與數據,賦能我們的真人客服代理人為客戶提供卓越服務。

  • For the second consecutive year, insurance carriers have significantly shifted policy structures and coverage features. Additionally, this was the second straight year where a significant number of plans were terminated by carriers. In each of the past two seasons, approximately 7% of the total plans in force have been canceled by the carriers, which compares to a historical average below 1%.

    連續第二年,保險公司大幅調整保單結構與保障特色。此外,這也是連續第二年有相當數量的方案被保險公司終止。在過去兩個投保季中,約有7%的在保方案總數被保險公司取消,相較之下,歷史平均值低於1%。

  • Beyond the elevated plan termination levels, the majority of our remaining beneficiaries saw a negative impact to at least one of their planned benefits on their legacy plans. This industry-wide dynamic created a market backdrop of elevated consumer shopping and engagement. As you will recall, our strategy heading into this AAP was to replicate the success of policyholder recapture and retention compared to a year ago.

    除了方案終止水準偏高之外,我們其餘多數受益人也在其既有方案中,至少有一項原本規劃的福利受到負面影響。這種全產業的動態,形成了消費者比以往更積極比價與互動的市場背景。如您所記得,我們在本次 AAP 前的策略,是複製相較去年在保戶回收與留存方面的成功。

  • Our operational focus to achieve this goal was to leverage our information and technology to work proactively with policyholders. Ahead of the season, we identified a subset of policies with higher change potential and anticipated coverage gaps based on each specific individual. In effect, we pulled forward as much of the work and disruption as possible.

    為達成此目標,我們的營運重點是運用資訊與科技,主動與保戶合作。在投保季開始前,我們辨識出一部分變動可能性較高的保單,並依每位個別人士預先推估可能出現的保障缺口。實際上,我們盡可能把工作與干擾提前處理。

  • The end result is that Selecto is a more valuable broker partner for both the policyholder and the carrier, especially in dynamic seasons like the past few years. When our customers call us looking for answers, our agents aren't starting from square one. Similarly, our carrier partners benefit from policies with better fit and persistency.

    最終結果是,Select 成為對保戶與保險公司而言更有價值的經紀合作夥伴,尤其是在像過去幾年這樣變動劇烈的投保季。當客戶致電我們尋求解答時,我們的代理人不必從零開始。同樣地,我們的保險公司合作夥伴也能受益於更契合需求且更具持續性的保單。

  • We measured the success of the strategy with our recapture rate, which is when our customers call us looking for answers, our agents aren't starting from square one. Similarly, our carrier partners benefit from policies with better fit and persistency.

    我們以回收率衡量此策略的成功;也就是當客戶致電我們尋求解答時,我們的代理人不必從零開始。同樣地,我們的保險公司合作夥伴也能受益於更契合需求且更具持續性的保單。

  • We measured the success of the strategy with our recapture rate, which was 33% this year. We're very proud of our recapture performance last year, but this year we delivered an even better result. This not only benefits market share, but each recapture means we preserve the cash flow from and the relationship with those beneficiaries.

    我們以回收率衡量此策略的成功,今年為33%。我們對去年回收表現感到非常自豪,但今年我們交出了更好的成果。這不僅有助於市占率,而且每一次回收都代表我們保留了來自這些受益人的現金流與關係。

  • To summarize, in another dynamic environment for Medicare Advantage, we are proud of the service we provided to our beneficiaries, which resulted in strong customer recapture rates and retention. The unique strengths of our model drove significant value to our policyholder customers and carrier partners and aligned with optimal profitability and cash flow for our senior segment.

    總結而言,在 Medicare Advantage 再次處於高度變動的環境下,我們為受益人提供的服務令我們深感自豪,並帶來強勁的客戶回收率與留存。我們模式的獨特優勢為保戶客戶與保險公司合作夥伴創造了顯著價值,並與 senior 事業部門的最佳獲利能力與現金流相一致。

  • Before we shift to healthcare services, let me take a moment to address last week's 2027 advance rate notice from CMS. Several carrier partners have already voiced disappointment with the advance rate notice, and we agree the preliminary rates don't reflect rising utilization and care costs. It's important to remember that these advanced rates are not final.

    在我們轉到醫療保健服務之前,讓我花一點時間說明 CMS 上週發布的 2027 年預先費率通知。多家保險公司合作夥伴已對該預先費率通知表達失望,我們也同意初步費率未能反映使用率與照護成本的上升。重要的是要記住,這些預先費率並非最終定案。

  • Coming on the heels of two highly disruptive seasons for Medicare beneficiaries, we believe CMS will receive feedback from the industry highlighting the potential negative implications to beneficiaries in advance of the final rate notice in April.

    在 Medicare 受益人已連續經歷兩個高度干擾的投保季之後,我們相信 CMS 將收到產業回饋,指出在4月發布最終費率通知前,這些初步費率可能對受益人造成的負面影響。

  • Regardless of the market backdrop, we will continue to prioritize outstanding service to our beneficiaries. Select's bespoke service model and information advantage remain highly valuable. And will likely become even more important as carriers focus on optimizing returns and policyholders work to interpret planned changes.

    無論市場背景如何,我們都將持續把為受益人提供卓越服務放在首位。Select 量身打造的服務模式與資訊優勢仍極具價值。而當保險公司聚焦於最佳化報酬、保戶努力解讀方案變更時,這些優勢很可能變得更加重要。

  • On [slide 6], I'd like to provide important context about the value of our Select Rx prescription drug delivery and adherent service. America's medication system is increasingly inefficient, confusing, and costly, issues that directly impact seniors' health. Recent Wall Street Journal articles highlighted two core problems. First, many seniors manage complex drug regimens prescribed by multiple physicians, which increases the risk of inappropriate medications and harmful interactions.

    在[第6頁]投影片,我想提供關於我們 Select Rx 處方藥配送與用藥依從性服務價值的重要背景。美國的用藥體系正變得愈發低效率、令人困惑且成本高昂,這些問題直接影響長者的健康。近期《華爾街日報》的文章指出兩個核心問題。第一,許多長者由多位醫師開立並管理複雜的用藥方案,這提高了不適當用藥與有害交互作用的風險。

  • Second, the widespread practice by many mail order pharmacies of repeatedly early filling 90 day prescriptions contributes to billions in wasted drugs when prescriptions change, while also creating complexity that undermines medication adherence. SelectRx was purpose built to address these systemic challenges head on.

    第二,許多郵購藥局普遍採行反覆提前配發90天處方的做法,當處方變更時會造成數十億美元的藥品浪費,同時也增加複雜度、削弱用藥依從性。SelectRx 的設計初衷,就是要正面解決這些系統性挑戰。

  • Our [30-day] time and date stamped medication strips reduce confusion, support adherence, and substantially cut waste when numbers of prescriptions change, which occurs for roughly 10% of our population each month.

    我們具[30天]時間與日期戳記的分裝藥條可降低混淆、支持依從性,並在處方數量變更時大幅減少浪費;而這類變更在我們的族群中約每月發生於10%的成員。

  • Just as importantly, our pharmacists review and consolidate each member's full medication profile. In 2025, they identified nearly 50,000 potential dosage or adverse interaction concerns. When such concerns arise, our pharmacists contact prescribing physicians in an attempt to remediate these concerns for impacted members. These conversations with prescribing physicians have resulted in changes to tens of thousands of prescriptions, helping to safeguard the patients we serve.

    同樣重要的是,我們的藥師會審視並整合每位會員完整的用藥檔案。在2025年,他們辨識出近50,000項潛在的劑量或不良交互作用疑慮。當出現此類疑慮時,我們的藥師會聯繫開立處方的醫師,嘗試為受影響的會員排除這些疑慮。這些與開立處方醫師的溝通,已促成數以萬計處方的調整,有助於守護我們所服務的病患。

  • This integrated approach is delivering real measurable outcomes, including an observed 20% reduction in beneficiary hospital days driven by better active medication adherence. These issues facing America's seniors are exactly why we built Select RX and why we continue working to improve a system that has long needed meaningful change. Before I turn the call to Ryan, I'd like to briefly touch on our January credit facility announcement and what it means for Select quote strategically.

    這種整合式方法正在帶來可量化的實質成果,包括因更佳的主動用藥依從性而使受益人住院天數觀察到減少 20%。美國高齡者所面臨的這些問題,正是我們打造 SelectRx 的原因,也是我們持續致力於改善一個長期亟需有意義變革之體系的原因。在我把電話交給 Ryan 之前,我想簡要談一下我們 1 月的信貸融資安排公告,以及這對 SelectQuote 策略層面的意義。

  • First, for those that have followed us, the optimization of our balance sheet has and continues to be a core priority of our strategy to drive shareholder value. In short, we believe our model should command a lower cost of capital. It is our intention to achieve that through continued operational improvement, growing cash flow, and the natural deleveraging that will follow.

    首先,對於一路關注我們的人而言,優化資產負債表一直且仍然是我們推動股東價值之策略的核心優先事項。簡而言之,我們相信我們的商業模式應該能夠取得更低的資金成本。我們的意圖是透過持續的營運改善、提升現金流,以及隨之而來的自然去槓桿化來達成。

  • We've made progress on this goal with previous refinancings, but to date have been limited by the near-term debt maturities which hindered our operational flexibility, especially in our senior Medicare Advantage business. As you can see on the charts on [slide 7], the new credit facility significantly extends our debt maturities to 2031.

    我們在先前的再融資上已朝此目標取得進展,但迄今仍受限於短期到期的債務,這限制了我們的營運彈性,尤其是在我們的高齡 Medicare Advantage(聯邦醫療保險優勢計畫)業務上。如你在[投影片 7]的圖表所見,新的信貸融資安排將我們的債務到期日大幅延長至 2031 年。

  • To be clear, our strategic focus does not change, and Select will continue to prioritize profitability and cash flow overgrowth. This enhanced operational flexibility simply allows us to capitalize on growth opportunities when market conditions support them.

    需要說明的是,我們的策略重點不變,Select 將持續把獲利能力與現金流置於成長之上。這項提升的營運彈性只是讓我們能在市場條件支持時,把握成長機會。

  • With that, let me turn the call to our CFO to detail our results, Ryan.

    接下來,我把電話交給我們的財務長 Ryan,請他說明我們的業績。

  • Ryan Clement - Chief Financial Officer

    Ryan Clement - Chief Financial Officer

  • Thanks, Tim. I'll pick it up on slide 8 with a summary of our consolidated financial results. As Tim noted, SelectQuote had a very strong quarter with revenue growth of 12% year over year, totaling $537 million.

    謝謝,Tim。我將從投影片 8 開始,概述我們的合併財務結果。如 Tim 所提,SelectQuote 本季表現非常強勁,營收年增 12%,達到 5.37 億美元。

  • The growth was driven by both our senior and healthcare services businesses, reflecting a strong AP and continued demand for our SelectRx service. Our EBO results were temporarily depressed due to the PBM reimbursement head that we highlighted last quarter.

    成長由我們的高齡與醫療保健服務兩大業務共同帶動,反映出強勁的 AP,以及市場對我們 SelectRx 服務的持續需求。由於我們在上一季提到的 PBM(藥品福利管理)報銷不利因素,我們的 EBO 結果短期受到壓抑。

  • In January we announced a new longer-term PBM agreement that provides increased visibility to these rates, which is important for our focus on predictable and profit-driven growth. The PBM headwind in healthcare services was offset by senior margins near record levels of 39%, driven by very strong efficiency in this AEP's marketing spend per approved policy.

    我們在 1 月宣布了一項新的長期 PBM 協議,提升了對這些費率的可視性,這對我們聚焦於可預測且以獲利驅動的成長非常重要。醫療保健服務中的 PBM 逆風,被高齡業務接近歷史高點的 39% 利潤率所抵銷;該利潤率主要來自本次 AEP 中,每張核准保單的行銷支出展現出非常強的效率。

  • In total, the quarter was excellent, as Tim mentioned. The operating momentum within both sides of the business is evident, and SelectQuote new balance sheet flexibility positions us well to navigate changing market conditions and capitalize on emerging opportunities.

    總體而言,本季表現非常出色,如 Tim 所提。兩大業務的營運動能清晰可見,而 SelectQuote 在資產負債表上的新彈性,使我們能更好地因應變動的市場環境並把握新興機會。

  • Moving to [slide 9] SelectQuote had a strong AEP despite another volatile market environment driven by carrier plan changes and terminations. Senior revenue of $262 million grew 2% on increased approved policy volumes. This AEP we were able to increase our agent population, which modestly aided volume. We expect these agents to become increasingly productive with experience this season and into the years ahead.

    接著看[投影片 9],儘管承保公司方案變更與終止導致市場環境再度波動,SelectQuote 在 AEP 期間仍表現強勁。高齡業務營收為 2.62 億美元,因核准保單量增加而成長 2%。本次 AEP 我們得以增加代理人數量,對保單量帶來些許助益。我們預期這些代理人將隨著本季累積經驗並在未來數年持續提升生產力。

  • The business was able to more than offset the productivity ramp of these new agents with strong marketing efficiency and other services revenue, which drove near record EBITDA margins of 39% in the quarter. This resulted in senior adjusted EBITDA of $102 million which is in line with last year's strong season. To echo Tim's sentiment, we are very pleased with the consistent execution in our senior business over the past four distinct seasons.

    該業務透過強勁的行銷效率與其他服務收入,足以抵銷新代理人生產力爬坡的影響,使本季 EBITDA 利潤率接近歷史高點的 39%。因此,高齡業務調整後 EBITDA 為 1.02 億美元,與去年強勁旺季的水準一致。呼應 Tim 的看法,我們對高齡業務在過去四個不同旺季中的穩定執行表現感到非常滿意。

  • Flipping a slide 10, we recognized strong demand for Selector X in our healthcare services segment. Members grew 17% year over year to [113,000]. Revenue grew even faster, expanding 26% year over year to $231 million as recently onboarded members continue to mature and take delivery of their full prescription regimen.

    切換到投影片 10,我們在醫療保健服務部門看到對 SelectRx 的強勁需求。會員數年增 17%,達到[113,000]。營收成長更快,年增 26% 至 2.31 億美元,因近期加入的會員持續成熟並開始領取其完整的處方用藥療程。

  • As we have noted, we expect growth to be more modest on a sequential basis in the near term as we continue to prioritize cash flow and profitability, much as we have in the senior business. That said, the PBM announcement earlier this year goes a long way toward providing that visibility, and we have conviction in healthcare services exiting fiscal 2026 at an annualized run rate of $40 million to $50 million of adjusted EBITDA.

    如我們先前所述,短期內我們預期按季成長將較為溫和,因為我們會持續優先考量現金流與獲利能力,這點與高齡業務相同。即便如此,今年稍早的 PBM 公告在提供可視性方面有很大助益;我們也有信心,醫療保健服務在 2026 會計年度結束時,調整後 EBITDA 的年化運行率可達 4,000 萬至 5,000 萬美元。

  • Most importantly, the demand for our SelectRx and the substantial value it provides to patients, caregivers, and carriers remains unchanged. We are focused on driving profitability and cash flow volume, and with improved PBM visibility and a more flexible balance sheet, we are well positioned to expand healthcare services where incremental margins are best. We will further optimize customer targeting to focus enrollments on the patients who benefit most from the SelectRx offering and also deliver the best economics to the business.

    最重要的是,市場對我們 SelectRx 的需求,以及其為病患、照護者與承保公司所帶來的重大價值,仍然不變。我們專注於推動獲利能力與現金流量的成長;在 PBM 可視性改善與資產負債表更具彈性之下,我們已具備良好條件,在增量利潤率最佳之處擴大醫療保健服務。我們也將進一步優化客戶鎖定策略,把投保/加入聚焦在最能從 SelectRx 方案中受益、同時也能為公司帶來最佳經濟效益的病患。

  • As a result, we expect membership to end fiscal 2026 flat to modestly down from the current [113,000] level while still generating [20% plus] year over year revenue growth. The market opportunity is clear there and with increased attention and demand we believe [SelectQuote] is very well positioned to be the partner of choice across the value chain.

    因此,我們預期 2026 會計年度末的會員數將與目前的[113,000]水準持平至小幅下降,但仍可帶來年增[20% 以上]的營收成長。市場機會相當明確;隨著關注度與需求提升,我們相信[SelectQuote]在價值鏈各環節都非常有條件成為首選合作夥伴。

  • Turning to slide 11, I'll review our life insurance business.

    接著看投影片 11,我將回顧我們的人壽保險業務。

  • Revenue grew 9% to $44 million driven by a strong quarter for final expense, where premiums increased 24% compared to a year ago. The business continues to execute at a high level and to deliver attractive margins in cash flow. Meanwhile, the term life business delivered flat premium levels in line with last year.

    營收成長 9% 至 4,400 萬美元,主要由終身費用(final expense)業務的強勁季度表現帶動,其保費較去年同期增加 24%。該業務持續維持高水準執行,並在現金流方面提供具吸引力的利潤率。同時,定期壽險業務的保費水準與去年持平。

  • Adjusted EBITDA for the life segment totaled $6 million down modestly year over year in the second quarter. Results reflect modest marketing expense pressure and increased competition within the term life business. Overall, the life division continues to deliver attractive returns and cash flows for shareholders.

    人壽部門第二季調整後 EBITDA 合計 600 萬美元,較去年同期小幅下降。結果反映行銷費用略有壓力,以及定期壽險業務競爭加劇。整體而言,人壽事業部仍持續為股東帶來具吸引力的報酬與現金流。

  • Speaking of the balance sheet, let me quickly detail our new credit facility on [slide 12]. As announced in January, [Selectro] closed on a new $415 million credit facility which benefits us in a number of ways. First and foremost, increased balance sheet flexibility through the elimination of our 2026 and 2027 debt maturities will allow us to operate strategically.

    談到資產負債表,讓我在[投影片 12]快速說明我們新的信貸融資安排。如 1 月所公告,[Selectro]完成一項新的 4.15 億美元信貸融資安排,並在多方面使我們受益。首先也是最重要的是,透過消除 2026 與 2027 年到期的債務而提升資產負債表彈性,將使我們能以策略性方式營運。

  • With a new maturity schedule that extends to 2031 and an increase in our peak season liquidity, Select has the optionality to invest in strategic trends like we are seeing with SelectRx and also capitalize on return opportunities within senior in real time.

    在新的到期時程延長至 2031 年、且旺季流動性提高之下,Select 具備選擇權可投資於我們在 SelectRx 所看到的策略性趨勢,並且也能即時把握高齡業務中的報酬機會。

  • Lastly, we remain aligned with both equity and debt investors in our strategic priorities to reduce leverage and drive to a lower cost of capital in the future. The new facility provides a future path for Select to lower the term facility interest rate by up to 100 basis points. Overall, it is a significant positive for our business and the latest in a series of successes as we continue to improve our capital structure.

    最後,我們在策略優先事項上仍與股權與債權投資人保持一致,致力於降低槓桿,並在未來推動更低的資本成本。新的融資安排為 Select 提供了未來將定期融資利率最多下調 100 個基點的路徑。整體而言,這對我們的業務是重大的正面因素,也是我們持續改善資本結構過程中一連串成功的最新成果。

  • I'll end on [slide 13] with a review of our updated guidance which Tim touched on earlier. I'll begin with the two distinct drivers of the change. First, the PBM reimbursement change, which we disclosed last quarter, drives an approximately [$20 million] headwind to fiscal 2026 EBITDA. Again, this impact will not recur beyond fiscal 2026.

    我將在[投影片 13]以回顧我們更新後的指引作結,Tim 先前已提及。我先從兩個造成變動的明確驅動因素談起。第一,PBM 給付(reimbursement)變更,我們在上一季已揭露,將對 2026 會計年度 EBITDA 造成約[2,000 萬美元]的不利影響。再次強調,這項影響在 2026 會計年度之後不會再發生。

  • Second, as Tim detailed, the decision to curtail marketing budget by a national carer partner is expected to drive an approximate $20 million headwind compared to our original expectations. As a result, we are revising our fiscal 2026 consolidated revenue range to $1.61 billion to $1.71 billion and our adjusted EBITDA range to $90 million to $100 million.

    第二,如 Tim 所詳述,一家全國性照護合作夥伴決定縮減行銷預算,預期相較於我們原先的預期將造成約 2,000 萬美元的不利影響。因此,我們將 2026 會計年度合併營收區間修正為 16.1 億美元至 17.1 億美元,並將調整後 EBITDA 區間修正為 9,000 萬美元至 1 億美元。

  • To be clear, we remain confident in our long-term outlook about the growth, profitability, and cash flow potential for our business. We stand by our previously announced fiscal 2026 targets of [20% plus] EBITDA margins for our senior division and an annualized adjusted EBITDA exit rate of $40 million to $50 million for our healthcare services division.

    需要說明的是,我們對公司長期在成長、獲利能力與現金流潛力方面的展望仍然有信心。我們維持先前公布的 2026 會計年度目標:資深(senior)事業部 EBITDA 利潤率達到[20% 以上],以及醫療保健服務事業部年化調整後 EBITDA 期末(exit rate)達 4,000 萬至 5,000 萬美元。

  • Lastly, as Tim alluded to, the change to our EBITDA forecast overshadows the meaningful year over year increase to operating cash flow, which we now forecast to total $25 million to 35 million for fiscal 2026. Aided by the increased operational flexibility from our significantly improved capital structure, we expect the business to continue to post meaningful cash flow gains in years to come. In fact, let me pass it back to Tim to expand on that a bit.

    最後,如 Tim 所提到的,我們 EBITDA 預測的變動掩蓋了營運現金流顯著的年增幅度;我們目前預估 2026 會計年度營運現金流總額為 2,500 萬至 3,500 萬美元。在我們大幅改善的資本結構所帶來的更高營運彈性助益下,我們預期未來幾年公司仍將持續繳出可觀的現金流成長。事實上,讓我把話交回給 Tim,請他再多補充一些。

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • Thanks, Ryan. Before we turn to your questions, let's review our cash flow generation on [slide 14]. We wanted to put a visual behind our strategic priority to drive profitable cash flow as it can be less apparent than our reported EBITDA, especially this year given the two discrete impacts to our guided range.

    謝謝,Ryan。在進入各位的提問之前,我們先在[投影片 14]回顧我們的現金流創造能力。

  • Here we depict our EBITDA on a cash basis, which is not considered future policy renewal commissions but does consider cash renewal payments received in the period. This is a clean way to view how profitable our business is on a cash basis in the current period.

    在這裡我們以現金基礎呈現 EBITDA;此口徑不納入未來保單續保佣金,但會納入期間內收到的續保現金款項。這是一個清楚的方式,用來觀察我們在當期以現金基礎衡量的獲利能力。

  • As you can see in the bar chart at left, despite the impact to our reported EBITDA, which considers future receivable accruals, we forecast significant growth in cash profitability. Specifically, we expect 2026 cash EBITDA to increase by approximately 20% compared to a year ago, which will help drive expected operating cash flow of $25 million to $35 million for fiscal '26.

    如左側長條圖所示,儘管我們的已揭露 EBITDA(其包含未來應收款的應計)受到影響,我們仍預期現金獲利能力將顯著成長。具體而言,我們預期 2026 年現金 EBITDA 將較去年增加約 20%,並將有助於推動 2026 會計年度預期營運現金流達 2,500 萬至 3,500 萬美元。

  • The key driver of that improvement is the operating cash efficiency. We continue to talk about in both our senior and healthcare services divisions, and senior agent marketing productivity gains have driven significant cash efficiency gains which drive operating cash flow and cash profitability for healthcare services and SelectRx, the upfront nature of cash recognition relative to our Medicare Advantage business will continue to drive consolidated operating cash flow as the business becomes a greater percentage of our overall mix.

    推動該改善的關鍵因素是營運現金效率。我們持續在資深與醫療保健服務兩個事業部強調這一點;資深代理人行銷生產力的提升帶動了顯著的現金效率改善,進而推動營運現金流與現金獲利能力。對於醫療保健服務與 SelectRx 而言,相較於我們的 Medicare Advantage 業務,現金認列更偏向前置的特性,將在該業務占我們整體組合比重提高時,持續推動合併營運現金流。

  • Cash flow is the key to driving increased shareholder value as we move through the quarters and years ahead, and we believe it is important for our investors and analysts to see that we are executing well. With that, let me now turn the call back to the operator to take your questions.

    隨著未來幾季與幾年的推進,現金流是提升股東價值的關鍵;我們也認為讓投資人與分析師看到我們執行到位非常重要。接下來,我把電話交回給主持人,開始進行提問。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Dave Windley, Jefferies.

    Jefferies 的 Dave Windley。

  • Dave Windley - Analyst

    Dave Windley - Analyst

  • Hi, thanks. Good morning. Thanks for taking my questions. I wanted to start, Tim, on the PBM, deal that you were able to strike during the quarter. Can you give us a little more detail? I think you emphasized that that makes this $20 million hit that you've had to take in fiscal '26, a one-time thing.

    嗨,謝謝。早安。謝謝讓我提問。Tim,我想先從 PBM 談起,也就是你們在本季達成的那筆協議。你能否提供更多細節?我想你強調過,這使得你們在 2026 會計年度必須承受的 2,000 萬美元影響屬於一次性。

  • Can I interpret that you've kind of re-established the economics of the relationship back to where they were or just provide us with some more detail about how that relationship is now structured.

    我是否可以理解為,你們已經把這段合作關係的經濟條件大致恢復到原本的水準?或者請再多提供一些目前這段合作關係的架構細節。

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • Yeah, Debbie, good morning. And we appreciate you joining this morning. Yeah, we were pleased with the announcement that we made earlier in January regarding the new PBM arrangement with a large PBM. This is important for us, really to be able to strike a multi-year term.

    好的,Debbie,早安。也感謝你今天早上加入。是的,我們對於 1 月稍早宣布與一家大型 PBM 達成新的 PBM 安排感到很高興。這對我們很重要,主要是能夠談成一個多年期的合約期限。

  • With the PBM, it provided the needed stability and predictability that we need, so we're very pleased with it. We're seeing that come absolutely in line with expectations, and we believe that helps really solidify our visibility moving forward.

    就 PBM 而言,這提供了我們所需要的穩定性與可預測性,因此我們非常滿意。目前我們看到的進展完全符合預期,我們相信這也確實強化了我們對未來的能見度。

  • Dave Windley - Analyst

    Dave Windley - Analyst

  • Okay, and then follow-up on, the announcement today I guess on the marketing budget at the major carrier I think I'm, I have a pretty strong suspicion of who that is, wondered what you know essentially what risk there might be of other carriers following that pattern.

    好的,接著追問一下,關於今天的公告,我想是關於主要保險公司行銷預算的部分;我大概很有把握知道是哪一家,想請問你們所了解的情況是,是否存在其他保險公司跟進這種做法的風險?

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • Yeah, so with respect to what we talked about on the call with the carrier that we outlined, they made a decision in December to pull back in strategic marketing investment as a way to significantly truncate. Growth that was not unique to select quote.

    是的,關於我們在電話會議中提到並概述的那家保險公司,他們在 12 月做出決定,回收(pull back)策略性行銷投資,作為大幅縮減成長的一種方式,而這並非 SelectQuote 獨有的情況。

  • This was a decision that was made across all third-party distribution, e-brokers and FMOs alike, and we're confident, Dave, in our ability to navigate through this. Certainly the carriers are going through a very challenging cycle, but the beneficiary demand is there. We've built a resilient, diversified.

    這項決策是針對所有第三方通路所做出的,包含電子經紀商(e-brokers)與 FMO 都一樣;Dave,我們有信心能夠順利因應。當然,保險公司正處於非常具挑戰性的循環之中,但受益人需求仍然存在。我們已建立一個具韌性、分散化的。

  • An agile business that can respond and we feel like we have a lot of levers at our disposal to be able to manage this with respect to other carrier partners. We don't anticipate anything of this level of materiality moving forward again, we're a very important part of the broad ecosystem. We drive high-quality volume not just for new members but how we perform from a retention standpoint, which is really critical in times like these when there's, hyperfocus on operating margins and retention.

    一個敏捷的業務體系可以做出回應,我們也覺得手上有很多槓桿可以運用,以便就其他保險公司合作夥伴的部分進行管理。我們不預期未來還會再出現同等重大程度的情況;我們是整體生態系中非常重要的一環。我們帶來高品質的量,不僅是新會員,還包括我們在留存(retention)方面的表現;在像現在這種對營運利潤率與留存高度聚焦的時期,這一點尤其關鍵。

  • Dave Windley - Analyst

    Dave Windley - Analyst

  • Got it thank you.

    了解,謝謝。

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • Thank you, Dave.

    謝謝你,Dave。

  • Operator

    Operator

  • Ben Hendrix, Capital Markets.

    Ben Hendrix,資本市場。

  • Ben Hendrix - Analyst

    Ben Hendrix - Analyst

  • Great, thank you very much. Just to follow-up on that last question, it seems like with this MA advance rate notice, coming in, a little more, a little softer than expected, and we know that the, there's a lot of hyper focus on margin enhancement. I'm just wondering to the extent that there are carriers out there who are, acknowledge your unique capabilities and have, acknowledge.

    很好,非常感謝。就追問上一個問題,看起來這次 MA 預先費率通知出來後,比預期稍微多一點、也稍微偏軟一些,而我們也知道市場非常聚焦在提升利潤率。我只是想問,在某種程度上,是否有一些保險公司認可你們獨特的能力並且已經認可。

  • The fact that you promote better fit and persistency, if there is an opportunity to kind of stand out and specialize ahead of 2027 where you may get a little bit more, share of marketing spend, that does come onto the kind of the DTC platform for next year. Any thoughts on kind of how you might be positioned there?

    你們推動更好的適配度與續保率這件事,是否有機會在 2027 年之前就先脫穎而出、提前專精,讓你們可能在行銷支出份額上多拿一些,而這些支出明年會更多地轉移到 DTC 平台上。你對你們可能在那裡的定位有什麼想法嗎?

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • Yeah, thank you, Ben. I appreciate you joining us as well. Just real quick on the CMS advance rate notice, as we said in the prepared remarks, we agree with the carriers that the current advance rate notice doesn't reflect the realities of where beneficiary utilization is and the cost of care, and we think there'll be a lot of continued dialogue between the MCOs and CMS on.

    是的,謝謝你,Ben。也很感謝你加入我們。先很快回應一下 CMS 的預先費率通知:如同我們在準備好的講稿中所說,我們同意保險公司的看法,目前的預先費率通知並未反映受益人使用情況與照護成本的現實,我們認為 MCO 與 CMS 之間還會有很多持續的對話。

  • On this particular matter, and we hope through that conversation when we get to the final rate notice in April that we'll see some improvement to your underlying question around our unique capabilities, we certainly agree. The market right now is in a period where, healthcare is, has a lot of financial stress, in the system, and that's a great opportunity for select, primarily around the efficiency of our model. As you can see in the second quarter results and the 39% margin for senior.

    就這個議題而言,我們希望透過這些對話,在 4 月的最終費率通知時能看到一些改善。回到你關於我們獨特能力的核心問題,我們當然同意。目前市場正處於一個醫療體系承受很大財務壓力的時期,這對少數業者而言是很好的機會,主要在於我們模式的效率。如你在第二季結果以及資深族群 39% 的利潤率所看到的。

  • Or if you look back over the past [three plus] years, we've really been able to deliver not only a very efficient model but a very high-quality model. And if you look at our retention results with respect to things we highlighted today, we think the book has performed very well and what we would kind of classify a turbulent market backdrop. You can see our recapture rate.

    或者如果你回頭看過去[三年多],我們確實不僅交付了非常高效率的模式,也交付了非常高品質的模式。而如果你看我們今天提到的留存結果,我們認為在我們所稱的動盪市場背景下,這個保單組合表現得非常好。你也可以看到我們的回收率。

  • I think that all bodes very well for our model because carriers will continue to look for quality and efficiency, and that provides more upside opportunities for us given our very, tight relationship with all the major payers.

    我認為這些都非常有利於我們的模式,因為保險公司將持續尋求品質與效率;而鑑於我們與所有主要付款方都維持非常緊密的關係,這也為我們帶來更多上行機會。

  • Ben Hendrix - Analyst

    Ben Hendrix - Analyst

  • Great, thank you. Just as a follow-up on the on the PBM contract, just in general, we're seeing more acceptance of these kinds of cost-plus structures in the, Cigna earlier this week announced in the FTC settlement as part of that it would go to a cost plus, PBM.

    很好,謝謝。再追問一下 PBM 合約:整體而言,我們看到市場對這類成本加成(cost-plus)結構的接受度提高;本週稍早 Cigna 在 FTC 和解中也宣布,作為其中一部分,它將轉向成本加成的 PBM。

  • And pharmacy reimbursement model. I'm just wondering if your new contract has any kind of cost-plus components to it on individual drugs and if that's something that you're seeing, could be a stabilizing factor in that in the Select RX business going forward. Thanks.

    以及藥局給付模式。我想請問你們的新合約在單一藥品上是否包含任何成本加成的組成,以及你們是否看到這可能成為未來 Select RX 業務的穩定因素。謝謝。

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • Yeah, maybe I'll make a few. Yeah, go ahead, [Rob. Go Ahead, Rob].

    是的,也許我先講幾點。好,你先請,[Rob。你先請,Rob]。

  • Robert Grant - President

    Robert Grant - President

  • Sorry, good question, Ben. I think as far as what you're seeing in momentum in the marketplace towards that, that's definitely right. I think that that's where, the market wants to go and where CMS wants it to go. Ours is similar to that with a guarantee and what I mean by that is there's less, there is no risk of kind of mac pricing updates and things that could be below market. So yes, a cost plus, effectively GER is where we are and it is a GER so.

    抱歉,問得很好,Ben。就你所看到市場朝那個方向的動能而言,確實如此。我認為那是市場想走的方向,也是 CMS 想推動的方向。我們的合約也類似,但帶有保證;我的意思是,像 MAC 定價更新等可能低於市場的情況,風險更小、甚至沒有。所以是的,成本加成,本質上以 GER 的方式呈現;而且它是一個 GER,所以。

  • We have that, not to the degree though what kind of ESI is talking about that's a standard cost plus with a higher, dispensing fee, and I do think the market is going to move towards that. You're seeing that with the IRA drugs, and I do think you'll see that overall, where the justification of service levels like ours, which is very high, is paid out through that. Through that dispensing fee so we're moving more towards that this one is very similar to that just not structured exactly like that.

    我們確實有,但程度上不如 ESI 所談的那種標準成本加成加上較高的調劑費(dispensing fee);我也確實認為市場會往那個方向走。你在 IRA 藥品上已經看到這種趨勢,我也認為整體都會如此;像我們這種服務水準非常高的模式,其服務合理性會透過那種方式獲得支付。也就是透過調劑費來支付;因此我們正更朝那個方向移動。這份合約非常類似,只是結構上不完全一樣。

  • Ben Hendrix - Analyst

    Ben Hendrix - Analyst

  • Thank you very much.

    非常感謝。

  • Operator

    Operator

  • George Sutton, Craig Hallum.

    George Sutton,Craig Hallum。

  • George Sutton - Analyst

    George Sutton - Analyst

  • Thank you. Tim, I wondered if you could go into more detail on what you mentioned our leverage at your disposal relative to the MA options given, this carrier move.

    謝謝。Tim,我想請你更詳細說明一下,你提到在這次保險公司動作之下,相對於 MA 選項,你們可運用的槓桿有哪些。

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • Hey, good morning, George. I appreciate you being here as well. Yeah, I mean, we have a unique model. We have a 50 state. Direct to consumer, business model, and we do have levers, first and foremost would be with respect to where we deploy marketing dollars, geographically that is, something that our model, can do versus, other field type models and an easier fashion. Also, we're going to continue to focus our investment on certain customer segments where we think the carriers want to grow.

    嗨,早安,George。也很感謝你在場。是的,我們有一個獨特的模式。我們在 50 州都有。直面消費者(DTC)的商業模式,而我們確實有一些槓桿;首先是我們如何在地理上配置行銷預算,這是我們的模式相較於其他偏外勤型模式更容易做到的。另外,我們也會持續把投資聚焦在某些客群區隔上,因為我們認為保險公司希望在那些區隔成長。

  • We can use, Snips as an example, where many carriers are going, and we do a lot of SNE business, and we're well aligned to grow where they want to grow. So that's another lever that we have, and at least we forget we have a diversified model beyond our, in a distribution business. We have a cash accretive SelectRx pharmacy, that can also factor into how we, our capital deployment decisions.

    我們可以用 Snips 作為例子,很多保險公司正往那裡走,而我們有很多 SNE 業務,且我們的成長方向與他們想成長的方向高度一致。所以那也是我們的一個槓桿;而且別忘了,除了我們的分銷業務之外,我們還有多元化的模式。我們有一個能帶來現金增益(cash accretive)的 SelectRx 藥局,也可以納入我們資本配置決策的考量。

  • George Sutton - Analyst

    George Sutton - Analyst

  • So, you mentioned that your new agreement, your new loan agreement gives you additional operating flexibility. I wondered if you could give us, and you mentioned you'd take advantage of it when the market supports it. You're obviously operating in kind of multiple markets now, so I'm just wondering how much change we might see in terms of, for example, an emphasis on health care services versus a deemphasis on. Medicare Advantage or I I'm not sure exactly what you meant by the flexibility, so I wondered if you'd give us a better sense there.

    所以,你提到你們的新協議、你們新的貸款協議讓你們有更多營運彈性。我想請你多說一些;你也提到會在市場支持時加以運用。你們現在顯然在多個市場運作,所以我想知道我們可能會看到多大的變化,例如更強調醫療服務、相對淡化。Medicare Advantage;或者我不太確定你所說的彈性具體指什麼,所以想請你讓我們更清楚。

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • Yeah, I mean, we have the utility, given the diversification of our model to pursue where we think the returns are best, certainly we have a highly synergistic model between our Medicare distribution platform and healthcare services, right? We're garnering a lot of that SelectRx growth through the conversations that we have with seniors on our MA platform.

    是的,我的意思是,鑑於我們模式的多元化,我們有能力去追求我們認為報酬最佳的方向;當然,我們的 Medicare 分銷平台與醫療服務之間具有高度協同效應,對吧?我們很多 SelectRx 的成長,都是透過我們在 MA 平台上與資深族群對話所帶來的。

  • So, I think that provides us a lot of. Utility around capital deployment decisions again, we are hopefully you're taking from our comments and our tone that we understand that there is some challenge and some noise out in the market right now, but we feel like we've built a very resilient, a very aligned, a very efficient model that gives us a lot of utility around how we deploy capital.

    所以,我認為這在資本部署決策方面再次為我們提供了很大的。效用;我們希望你們能從我們的評論與語氣中感受到,我們理解目前市場上確實存在一些挑戰與雜音,但我們覺得我們已建立了一個非常具韌性、非常一致、非常高效率的模式,讓我們在如何部署資本方面擁有很大的效用。

  • We've also shared today. Kind of the last slide around the growing cash flow dynamic of the business, and that's something that we would point, investors to despite the unfortunate events and the guide down on the 606 EBITDA, we are continuing to grow our cash EBITDA. We are continuing to grow our operating leverage, and that will be the focus for the business and that will be the lens in which we look around capital deployment.

    我們今天也分享了。關於業務現金流動態成長的最後一張投影片;我們想提醒投資人注意的是,儘管發生了不幸事件,且606 EBITDA指引下修,我們仍在持續成長我們的現金EBITDA。我們也持續提升營運槓桿,而這將是業務的重點,也將是我們審視資本部署的視角。

  • George Sutton - Analyst

    George Sutton - Analyst

  • Understand. Thank you.

    了解。謝謝。

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • Thank you, George.

    謝謝你,George。

  • All right that's additional questions.

    好,還有其他問題。

  • Operator

    Operator

  • [Patrick McCann].

    [Patrick McCann]。

  • Patrick McCann - Analyst

    Patrick McCann - Analyst

  • Hey, good morning. Thanks for Taking my question. I just wanted to, ask you a little bit about the SelectRx situation. Given the scale that you've reached, I'm wondering how that affected your negotiating position, in this most recent discussion, maybe if you could compare that to previous agreements you've entered, any, significant, positive effect on your negotiating position given that scale.

    嗨,早安。謝謝讓我提問。我想請教一下SelectRx的情況。考量你們已達到的規模,我想知道這在最近一次討論中如何影響你們的談判地位;也許你們可以和先前簽訂的協議做個比較,這樣的規模是否對你們的談判地位帶來任何顯著、正面的影響。

  • Robert Grant - President

    Robert Grant - President

  • Yeah, it definitely affects our negotiating ability. I mean, we are starting to get to a point where we do have some leverage, right? We, or just say a deeper partnership, right? We have, 100+,000 extremely complex members that we successfully. Engage with, deal with, and drive their adherence to a good place and more actually importantly in this group their compliance towards the times that they take those meds and things like that we've showed the past, right? We've got data now proving that helps bend the kind of cost curve of hospitalizations and other things we're starting to partner even deeper to do more whether that's, enhanced.

    是的,這確實會影響我們的談判能力。我的意思是,我們正開始走到一個我們確實擁有一些槓桿的位置,對吧?或者說是一種更深度的合作夥伴關係,對吧?我們有10萬名以上極其複雜的會員,我們成功地。與他們互動、服務,並把他們的用藥依從性推進到良好水準;更重要的是,在這個族群中,他們在按時服藥等方面的遵從性,我們過去已經展示過,對吧?我們現在有數據證明,這有助於壓低住院等成本曲線;我們也開始更深度合作去做更多事情,不論是強化的。

  • MDM services, remote therapeutic monitoring where we can really make sure they are taking those at the times we think they are and other things that help drive not only data to our carrier partners but ultimately action if somebody is not managing their healthcare the way that they should and with a population that you know has [three plus] chronic conditions.

    MDM服務、遠距治療監測(remote therapeutic monitoring),讓我們能真正確認他們是否在我們認為的時間點服藥,以及其他有助於推動數據(不僅提供給我們的保險承保方合作夥伴)但最終也能促成行動的措施;如果有人沒有以應有的方式管理其健康照護,尤其是面對你知道有[三種以上]慢性病的族群。

  • Is on 10 or more meds that's extremely important so I think or we know now that has given us significantly more negotiating power and we're being viewed as a valued partner which is why we were able to get to where we were on the pharmacy negotiation with the PBM.

    而且正在服用10種或以上藥物,這就極其重要;所以我認為——或者我們現在知道——這已經讓我們擁有顯著更強的談判力,而且我們被視為一個有價值的合作夥伴,這也是為什麼我們能在與PBM的藥局談判中達到目前的結果。

  • Patrick McCann - Analyst

    Patrick McCann - Analyst

  • Great. And then, my follow-up, just with staying on SelectRX, given where the Kansas facility is in its ramp, I was just wondering if you could talk a little bit about how much incremental volume, could be absorbed, with that facility before you need any meaningful new capital investment there.

    很好。接著我的追問,仍然關於SelectRx,考量堪薩斯設施目前的爬坡進度,我想請你談談在那個設施需要任何有意義的新資本投資之前,還能吸收多少增量的量能。

  • Robert Grant - President

    Robert Grant - President

  • Yeah, that facility, has actually really high, kind of, you can have a lot of customers in there, so lots of room for expansion, but actually a lot of, a lot today in the machinery that we've bought. We've bought much more efficient, machinery, I think we've been open about the Enviion and what that does and how many customers we can drive through that, but more importantly how we can do it with less staff and ultimately drive our cost down and our compliance and kind of everything else up.

    是的,那個設施其實有非常高的——算是——容量,你可以在那裡容納很多客戶,所以擴張空間很大;但其實我們今天在我們購置的機器設備上已經投入很多。我們買了效率高得多的設備;我想我們也公開談過Enviion,以及它能做什麼、我們可以透過它處理多少客戶;但更重要的是,我們如何用更少的人力做到這些,最終降低成本,同時提升我們的合規性以及其他各方面的表現。

  • We're also working on a lot of new technology initiatives to try to take, I call it more of an archaic industry in the way that it's designed. And modernize that so, to fit our needs because we have a different workflow right than most pharmacies, we're pretty far along in that now and we're about to roll some really exciting things out that should even add more to efficiency but more importantly that allows us to use AI and other tools to drive efficiency in the future and that's what we're trialing in that Kansas facility, that.

    我們也在推進許多新的技術計畫,試圖把——我稱之為——在設計方式上較為老派的產業。加以現代化,以符合我們的需求;因為我們的工作流程與大多數藥局不同,對吧?我們在這方面已經相當深入,並且即將推出一些非常令人振奮的內容,這應該能進一步提升效率;更重要的是,這讓我們能使用AI與其他工具,在未來持續推動效率,而這正是我們在堪薩斯設施中試行的內容,這。

  • Will allow us then to kind of retrofit our other facilities to be similar so we're very confident we can drive that down all leading to a big growing cash flow line for us. We've got a lot of gross margin there we just would like to get our gross to net margin or net to gross margin up even higher than we have it today and we think there's a ton of opportunity there.

    將使我們之後能把其他設施改造得更相似;因此我們非常有信心能把這些成本壓下來,而這一切都將帶動我們現金流大幅成長。我們那裡有很大的毛利空間;我們只是希望把毛利到淨利(gross to net margin)或淨利到毛利(net to gross margin)的表現提升到比今天更高,我們認為那裡有大量機會。

  • Patrick McCann - Analyst

    Patrick McCann - Analyst

  • Thank you. That's it for me.

    謝謝。我就這些。

  • Operator

    Operator

  • There are no further questions at this time. I will now turn the call back to Tim Danker, CEO, for closing remarks.

    目前沒有其他問題。我現在把電話交回給執行長Tim Danker作結語。

  • Timothy Danker - Chief Executive Officer, Director

    Timothy Danker - Chief Executive Officer, Director

  • I want to thank you all for joining us again today. Although we've encountered some unexpected headwinds this fiscal year, we remain focused on narrowing the spread of outcomes and controlling the controllables. We continue to execute well operationally and with the diversification of our business model, no company in the sector is better positioned to navigate business cycles.

    感謝各位今天再次加入我們。儘管本財年我們遭遇了一些意料之外的逆風,我們仍專注於縮小成果差距,並控制可控的事項。我們持續在營運上執行良好;隨著我們商業模式的多元化,本產業中沒有任何公司比我們更具備穿越景氣循環的有利位置。

  • We have the operating model. We have the competitive advantages, and we now have the balance sheet flexibility to significantly expand cash flows in the years to come. I want to thank you again. Everyone have a good day.

    我們有營運模式。我們有競爭優勢,而我們現在也具備資產負債表的彈性,能在未來幾年大幅擴張現金流。再次感謝各位。祝大家有美好的一天。

  • Operator

    Operator

  • This concludes today's call. Thank you for attending. (Operator Instructions)

    今天的電話會議到此結束。感謝各位參與。(接線員指示)